Compare OOMA & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | STRO |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.1M | 85.0M |
| IPO Year | 2015 | 2018 |
| Metric | OOMA | STRO |
|---|---|---|
| Price | $11.17 | $10.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 8 |
| Target Price | ★ $19.00 | $18.29 |
| AVG Volume (30 Days) | ★ 296.1K | 115.4K |
| Earning Date | 12-08-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $264,115,000.00 | $105,646,000.00 |
| Revenue This Year | $7.29 | $63.08 |
| Revenue Next Year | $17.91 | N/A |
| P/E Ratio | $136.81 | ★ N/A |
| Revenue Growth | ★ 4.22 | N/A |
| 52 Week Low | $9.79 | $5.23 |
| 52 Week High | $15.65 | $21.50 |
| Indicator | OOMA | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 45.57 | 71.68 |
| Support Level | $11.19 | $8.49 |
| Resistance Level | $11.78 | $12.18 |
| Average True Range (ATR) | 0.46 | 0.85 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 3.81 | 65.63 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.